{
  "schemaVersion": 2,
  "eyebrow": "Dermatology",
  "title": "Telogen Effluvium",
  "summary": "Evaluate diffuse shedding by anchoring onset to a trigger, excluding patterned and inflammatory alopecia, and correcting identifiable systemic, nutritional, or medication causes. Acute telogen effluvium usually resolves after trigger removal; shedding beyond 6 months warrants reassessment for chronic disease or a competing diagnosis.",
  "seoDescription": "Physician approach to telogen effluvium: trigger-based diagnosis, targeted testing, differentiation from androgenetic alopecia, biopsy indications, and prognosis.",
  "clinicalQuestion": "How should clinicians diagnose, investigate, and manage acute or chronic telogen effluvium?",
  "specialty": "Dermatology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "telogen effluvium",
    "diffuse hair shedding",
    "chronic telogen effluvium",
    "female pattern hair loss",
    "hair pull test",
    "scalp biopsy"
  ],
  "keyTakeaways": [
    "Diffuse shedding beginning about 2-3 months after febrile illness, surgery, delivery, weight loss, medication exposure, or other physiologic stress strongly supports acute telogen effluvium; persistence beyond 6 months defines chronic shedding and should prompt renewed etiologic and diagnostic assessment. [8][13][16]",
    "Do not diagnose chronic telogen effluvium until competing causes of diffuse alopecia, particularly androgenetic alopecia, diffuse alopecia areata, thyroid disease, iron deficiency, nutritional disturbance, and medication-related loss, have been considered. [3][4][12]",
    "Scalp biopsy is most useful when diffuse shedding persists beyond 6 months or clinical examination and trichoscopy cannot distinguish chronic telogen effluvium from androgenetic alopecia or diffuse alopecia areata. [4][17]",
    "Management is trigger-directed: replace or discontinue a suspected causative drug when clinically feasible, treat documented systemic or nutritional disease, and set expectations that acute shedding is usually self-limited. [16][17]",
    "Topical minoxidil is commonly used but has not been proven to promote recovery in telogen effluvium; avoid presenting it as required therapy for an otherwise self-limited acute episode. [6][15]"
  ],
  "sections": [
    {
      "id": "triage-and-clinical-pattern",
      "eyebrow": "First Visit",
      "heading": "Identify the shedding pattern and decide whether telogen effluvium is plausible",
      "intro": "Use chronology and distribution before ordering broad laboratory panels.",
      "paragraphs": [
        "Classify the presentation as acute when diffuse shedding has lasted less than 6 months and chronic when it persists beyond 6 months. Acute telogen effluvium typically begins 2-3 months after a trigger, although diffuse shedding may present 1-6 months after a precipitating event. High-yield exposures include febrile or severe systemic illness, major surgery, childbirth, pregnancy-related events, weight loss or caloric restriction, emotional or physiologic stress, thyroid disease, medications, and nutritional disturbance. [7][8][11][16]",
        "A history of more than 100 shed hairs daily or collection of 100 or more hairs over 24 hours supports excessive shedding, but neither measure establishes etiology. Ask specifically about timing of infection, hospitalization, surgery, postpartum hemorrhage, restrictive diets, rapid weight loss, and all prescription, over-the-counter, and hormonal drugs; anticoagulants, anticonvulsants, and high-dose contraceptives are among reported medication associations. [15][18]",
        "The working diagnosis should remain provisional when thinning is patterned, progression is gradual rather than abruptly shedding-predominant, or there is a strong family history of androgenetic alopecia. Androgenetic alopecia is the most common competing diagnosis in diffuse loss and may coexist with telogen effluvium; trichoscopy can help distinguish these entities. [3][24]"
      ],
      "bullets": [
        "Favor acute telogen effluvium: abrupt diffuse shedding after a plausible trigger, often with visible short frontal regrowth as the episode resolves. [16]",
        "Reconsider telogen effluvium: shedding with persistent or progressive patterned thinning, a course longer than 6 months, or no satisfactory explanation after directed evaluation. [3][13][17]",
        "Expand the differential: diffuse alopecia areata, anagen effluvium, systemic disease, hypothyroidism, iron deficiency, zinc deficiency, and protein or caloric restriction can present with diffuse loss. [3][12]"
      ],
      "subsections": [],
      "table": {
        "caption": "Clinical branches that change the next diagnostic step. [3][4][12][16][17]",
        "columns": [
          "Clinical pattern",
          "Most consequential alternative",
          "Next step"
        ],
        "rows": [
          [
            "Abrupt diffuse shedding 2-3 months after fever, surgery, delivery, weight loss, or stress; duration <6 months",
            "Acute telogen effluvium",
            "Identify and remove or treat the trigger; provide a time-limited prognosis rather than reflexive hair-growth treatment. [8][16][17]"
          ],
          [
            "Diffuse shedding persists >6 months or fluctuates over months",
            "Chronic telogen effluvium; repeated triggers; androgenetic alopecia",
            "Reassess medications, nutrition, thyroid and systemic disease; use trichoscopy and consider scalp biopsy when the distinction remains uncertain. [4][13][17]"
          ],
          [
            "Patterned thinning, strong family history, or suspected follicular miniaturization",
            "Androgenetic alopecia, with or without concurrent telogen effluvium",
            "Use trichoscopy; obtain biopsy if the diagnosis will alter management and clinical findings remain equivocal. [3][4]"
          ],
          [
            "Diffuse loss without a clear trigger or with atypical clinical findings",
            "Diffuse alopecia areata, anagen effluvium, systemic or nutritional alopecia",
            "Direct testing to the history and examination; biopsy when diffuse alopecia areata or another competing diagnosis cannot be excluded clinically. [3][4][12]"
          ]
        ]
      }
    },
    {
      "id": "targeted-workup",
      "eyebrow": "Diagnostic Workup",
      "heading": "Use targeted testing to find reversible causes, not to confirm telogen effluvium",
      "intro": "No serum laboratory marker reliably diagnoses telogen effluvium.",
      "paragraphs": [
        "Obtain testing when the history or examination identifies a plausible reversible branch: thyroid disease, blood loss or inadequate iron intake, restrictive dieting or malnutrition, renal or liver disease, or other systemic illness. Thyroid disease, severe iron deficiency anemia, zinc deficiency, and severe protein, fatty-acid, or caloric restriction are recognized causes of diffuse telogen hair loss. [11][12]",
        "Serum ferritin can document iron deficiency, but ferritin is not a stand-alone diagnostic test for telogen effluvium. In one comparative study, mean ferritin in telogen effluvium was 24.27 ng/mL and an optimal discriminating cutoff was 24.45 ng/mL; this finding does not establish a universal treatment target. Proposed ferritin thresholds for hair-loss prevention vary, with >40 micrograms/L used in one study and >15 micrograms/L considered sufficient by some authors. [10][18]",
        "Order ferritin to evaluate suspected iron deficiency rather than treating a marginal value as proof of causation. Evidence linking iron deficiency without anemia to chronic diffuse loss remains controversial; supplementation is most defensible for documented deficiency or a clinical iron-deficiency syndrome rather than indefinite empiric use. [2][12]",
        "A medication review is a diagnostic intervention. When a drug is temporally plausible, weigh substitution or discontinuation against the risk of interrupting essential therapy; do not stop anticoagulants, anticonvulsants, or hormonal agents solely on the basis of shedding without coordinating with the prescribing clinician. Suspected causative drugs should be replaced or discontinued when feasible. [17][18]"
      ],
      "bullets": [
        "Use ferritin when blood loss, low dietary iron intake, restrictive eating, anemia, or other iron-deficiency risk is present; interpret values in the broader clinical context. [12][18]",
        "Assess thyroid function when symptoms, history, or medication exposure suggests thyroid disease, because hypothyroidism is a recognized cause of diffuse alopecia. [3][4][12]",
        "Assess nutritional exposures directly: recent crash dieting, chronic starvation, inadequate protein or caloric intake, and risk factors for zinc deficiency change the cause-directed plan. [12]",
        "Treat active scalp psoriasis or seborrheic dermatitis when present because scalp inflammatory disease may contribute to ongoing shedding. [17]"
      ],
      "subsections": [],
      "table": {
        "caption": "Interpretation of common workup branches in diffuse shedding. [3][10][12][18]",
        "columns": [
          "Finding or risk factor",
          "Interpretation",
          "Action"
        ],
        "rows": [
          [
            "Plausible trigger 2-3 months before abrupt shedding",
            "Supports acute telogen effluvium but does not exclude coexisting androgenetic alopecia. [8][16]",
            "Address the trigger and monitor for reduction in shedding and regrowth. [16][17]"
          ],
          [
            "Low ferritin with clinical risk for iron deficiency",
            "Confirms iron deficiency when interpreted with the clinical context; the ferritin threshold relevant to hair outcomes is unsettled. [10][12][18]",
            "Treat documented deficiency and investigate the source of iron loss or inadequate intake. [4][12]"
          ],
          [
            "Thyroid dysfunction",
            "A recognized systemic cause of diffuse hair loss. [3][4][12]",
            "Treat the thyroid disorder and reassess shedding over time. [4]"
          ],
          [
            "Severe caloric, protein, fatty-acid, or zinc deficiency exposure",
            "Can induce diffuse telogen hair loss. [12]",
            "Correct the nutritional deficiency and discontinue restrictive intake when possible. [12]"
          ],
          [
            "Normal targeted evaluation with shedding >6 months",
            "Primary chronic telogen effluvium remains possible, but androgenetic alopecia and diffuse alopecia areata require exclusion. [4][13]",
            "Perform trichoscopy; proceed to scalp biopsy if uncertainty persists. [3][4][17]"
          ]
        ]
      }
    },
    {
      "id": "trichoscopy-and-biopsy",
      "eyebrow": "Diagnostic Escalation",
      "heading": "Use trichoscopy and biopsy when chronic diffuse loss could be androgenetic alopecia or alopecia areata",
      "intro": "Biopsy is a discriminator, not a routine test for a clear acute episode.",
      "paragraphs": [
        "Reserve scalp biopsy for diffuse shedding that lasts longer than 6 months, a discordant history and examination, or persistent uncertainty between chronic telogen effluvium, androgenetic alopecia, and diffuse alopecia areata. Multiple biopsies improve diagnostic accuracy. A biopsy may be necessary because chronic telogen effluvium can overlap clinically with androgenetic alopecia and because diffuse alopecia areata may require exclusion. [4][17]",
        "On scalp biopsy, chronic telogen effluvium shows increased telogen hairs; one review reports an anagen:telogen ratio of approximately 8:1 compared with 14:1 in normal scalp. In a large chronic telogen effluvium series using 4-mm horizontal sections, the mean terminal-to-velluslike ratio was 9:1, with 89% terminal hairs in anagen and 11% in telogen. [5][17]",
        "Follicular miniaturization argues against isolated telogen effluvium and favors androgenetic alopecia. Peribulbar infiltrate also is not expected in uncomplicated telogen effluvium. In the comparative histology series, significant inflammation and fibrosis occurred in 37% of androgenetic alopecia cases versus 10%-12% of chronic telogen effluvium cases and controls. [5][17]"
      ],
      "bullets": [
        "Do not biopsy a classic, short-duration, trigger-associated acute episode that is already improving unless examination suggests another alopecia. [16][17]",
        "Biopsy chronic diffuse loss when the result will decide between reassurance and cause-directed management of telogen effluvium versus treatment of androgenetic alopecia or another alopecia. [4][17]",
        "Interpret pathology with the clinical timeline: chronic telogen effluvium is a diagnosis made after exclusion of other causes of diffuse alopecia. [4]"
      ],
      "subsections": [],
      "table": {
        "caption": "Biopsy findings that help separate chronic telogen effluvium from competing diffuse alopecias. [5][17]",
        "columns": [
          "Histologic feature",
          "Chronic telogen effluvium",
          "Implication"
        ],
        "rows": [
          [
            "Anagen:telogen ratio",
            "Approximately 8:1 versus 14:1 in normal scalp. [17]",
            "Supports increased telogen representation in the appropriate clinical setting. [17]"
          ],
          [
            "Terminal:velluslike ratio",
            "Approximately 9:1 in one chronic telogen effluvium series. [5]",
            "Preserved terminal predominance helps distinguish from miniaturizing androgenetic alopecia. [5][17]"
          ],
          [
            "Follicular miniaturization",
            "Not expected in isolated telogen effluvium. [17]",
            "Favors androgenetic alopecia when present. [17]"
          ],
          [
            "Peribulbar infiltrate",
            "Not expected in uncomplicated telogen effluvium. [17]",
            "Should prompt consideration of an alternate inflammatory or autoimmune alopecia. [17]"
          ]
        ]
      }
    },
    {
      "id": "management-and-monitoring",
      "eyebrow": "Management",
      "heading": "Treat the trigger, set a realistic recovery timeline, and avoid unsupported routine therapy",
      "intro": "Acute telogen effluvium generally requires correction and observation rather than aggressive hair-directed treatment.",
      "paragraphs": [
        "For acute telogen effluvium, correct the identified precipitant: treat thyroid disease or other systemic illness, address documented iron or nutritional deficiency, stop or substitute a likely causative medication when clinically safe, and treat concurrent scalp psoriasis or seborrheic dermatitis. If no trigger is found, explain that a cause remains unidentified in approximately one-third of acute cases and schedule reassessment rather than assigning a permanent diagnosis prematurely. [16][17]",
        "Counsel that acute telogen effluvium is usually self-limited. About 95% of acute cases remit in one review, and most patients regain normal fullness within 6-9 months; restoration of baseline thickness can take up to 18 months. Short regrowing frontal hairs on follow-up support recovery. [6][16]",
        "Topical minoxidil has theoretical effects on the hair cycle but has not been proven to promote recovery in telogen effluvium. It may be discussed only as an individualized adjunct, particularly when coexisting androgenetic alopecia is suspected, while explicitly distinguishing this from evidence-based trigger correction. [6][15]",
        "Avoid empiric long-term nutritional supplementation in the absence of a severe or documented deficiency. Nutritional supplements are described as appropriate for severe deficiency and not recommended for long-term routine use; ferritin, zinc, and vitamin D abnormalities may be common in populations with and without chronic telogen effluvium. [2][10]"
      ],
      "bullets": [
        "Reassess before 6 months if shedding accelerates, pattern loss becomes evident, examination becomes atypical, or a new systemic illness or medication exposure occurs. [3][16]",
        "At 6 months of ongoing shedding, revisit recurrent triggers and targeted laboratory findings, perform trichoscopy, and consider biopsy if androgenetic alopecia or diffuse alopecia areata remains plausible. [4][13][17]",
        "Use objective follow-up documentation of shedding burden, distribution, and regrowth rather than relying only on a single hair-count estimate. Hair collections can decline over weeks as telogen effluvium improves. [15]"
      ],
      "subsections": [
        {
          "heading": "Chronic telogen effluvium",
          "paragraphs": [
            "Chronic telogen effluvium is defined by diffuse telogen hair loss persisting longer than 6 months and is often fluctuating. Before labeling it primary chronic telogen effluvium, search for repeated or persistent triggers, including nutritional deficiency, thyroid disease, infection, systemic illness, and medications; the longer shedding continues, the more likely multiple or recurrent triggers contribute. [13][17]",
            "When chronic telogen effluvium is confirmed after exclusion of competing causes, prioritize expectation-setting and longitudinal assessment. Chronic disease has a different prognosis from androgenetic alopecia, so confirming the diagnosis with trichoscopy or biopsy when uncertain prevents unnecessary or misdirected long-term therapy. [3][4]"
          ],
          "bullets": []
        }
      ],
      "table": {
        "caption": "Management and monitoring by course. [6][13][16][17]",
        "columns": [
          "Course",
          "Immediate action",
          "Monitoring and escalation"
        ],
        "rows": [
          [
            "Acute shedding <6 months with a clear trigger",
            "Remove or treat the trigger; replace or discontinue a suspected culprit drug when safe. [16][17]",
            "Expect improvement over months; reassess if the trajectory is not improving or a competing alopecia becomes apparent. [6][16]"
          ],
          [
            "Acute shedding without an identified trigger",
            "Use targeted history, examination, and testing for reversible systemic, thyroid, iron, and nutritional causes. [12][16]",
            "Reevaluate rather than assuming a fixed chronic disorder; about one-third of acute episodes have no identified cause. [16]"
          ],
          [
            "Persistent shedding >6 months",
            "Reassess repeated triggers, medications, systemic disease, and nutritional exposures. [13][17]",
            "Use trichoscopy and biopsy when androgenetic alopecia or diffuse alopecia areata remains uncertain. [3][4][17]"
          ],
          [
            "Concurrent patterned thinning or histologic miniaturization",
            "Treat as possible coexisting androgenetic alopecia rather than attributing all loss to telogen effluvium. [3][17]",
            "Track pattern progression separately from resolution of shedding. [3][24]"
          ]
        ]
      }
    }
  ],
  "faq": [
    {
      "question": "Is a ferritin target required before telogen effluvium will recover?",
      "answer": "No universal ferritin target for hair recovery is established. Ferritin helps identify iron deficiency, but proposed thresholds vary: one study used >40 micrograms/L as desirable, whereas others have considered >15 micrograms/L sufficient. Treat documented deficiency and its cause rather than pursuing indefinite empiric supplementation. [10][12][18]"
    },
    {
      "question": "When should topical minoxidil be offered for telogen effluvium?",
      "answer": "Do not present topical minoxidil as required treatment for acute telogen effluvium; it has theoretical benefit but has not been proven to accelerate recovery. Consider individualized discussion when concomitant androgenetic alopecia is suspected, while continuing trigger-directed care. [6][15]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2817326",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 2,
      "title": "Nutritional Supplements and Hair Loss—Limitations ... - JAMA Network",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamadermatology/articlepdf/2806310/jamadermatology_obijiofor_2023_le_230001_1692117352.46104.pdf?resultClick=1",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 3,
      "title": "Telogen Effluvium – a review of the science and current obstacles",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0923181121000086",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 4,
      "title": "CHRONIC TELOGEN EFFLUVIUM - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0733863505703983",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 5,
      "title": "Chronic telogen effluvium: Increased scalp hair shedding in middle-aged women - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0190962296901139",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 6,
      "title": "Covid Induced Telogen Effluvium (CITE) : Indian Dermatology Online Journal",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/idoj/fulltext/2022/13040/covid_induced_telogen_effluvium__cite___an_insight.1.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 7,
      "title": "Alopecia in general medicine - ScienceDirect.com",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1470211824027490",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 8,
      "title": "Chronic diffuse alopecia in women: a retrospective review of ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/ijd.16921",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 9,
      "title": "Use of 5% Topical Minoxidil Application for Telogen Effluvium: An ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17844",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 10,
      "title": "Chronic telogen effluvium in women : Journal of the Egyptian Women's Dermatologic Society",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/jewds/_layouts/15/oaks.journals/downloadpdf.aspx?an=01287624-202118030-00008",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 11,
      "title": "Role of ferritin, vitamin D, and thyroid... : Al-Azhar Assiut Medical Journal",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/aamj/_layouts/15/oaks.journals/downloadpdf.aspx?an=01157422-202119030-00015",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 12,
      "title": "An Analytical Study of Serum Ferritin, Vitamin D, and Thyroid ...",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/ijdd/fulltext/2022/09010/an_analytical_study_of_serum_ferritin%2C_vitamin_d%2C.2.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 13,
      "title": "Systematic approach to hair loss in women - Trüeb - 2010 - JDDG",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/j.1610-0387.2010.07261.x",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 14,
      "title": "Telogen effluvium related to post severe Sars‐Cov‐2 infection ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/dth.14547",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 15,
      "title": "Telogen Effluvium - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=696c5ba7dc96372a6deae059",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 16,
      "title": "Telogen Effluvium: A Review of the Literature - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320655",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 17,
      "title": "Telogen Effluvium: A Review of the Literature",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7320655",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 18,
      "title": "The Diagnostic Value of Serum Ferritin for Telogen Effluvium: A Cross-Sectional Comparative Study - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882421",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "C1 PAGE.indd - AAP Publications",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/pediatricsinreview/issue-pdf/828505",
      "authors": "publications.aap.org",
      "host": "publications.aap.org"
    },
    {
      "number": 20,
      "title": "Comparative evaluation of two Unani formulation combinations in the treatment of telogen effluvium: A randomized, single-blind clinical trial - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2097382926000107",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 21,
      "title": "Male Type Alopecia - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/male-type-alopecia",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 22,
      "title": "Low-dose oral minoxidil beyond androgenetic alopecia",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2950198926000589",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 23,
      "title": "Systematic review: Impact of stem cells-based therapy, and platelet ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2352320423000652",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 24,
      "title": "Dengue-associated telogen effluvium: A report of 14 patients",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1027811716301604",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamadermatology/fullarticle/2817326",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "only topical minoxidil is associated with telogen effluvium (TE) due to irritation, while oral minoxidil improves TE, and when TE happens it is",
      "score": 0.39138326
    },
    {
      "number": 2,
      "title": "Nutritional Supplements and Hair Loss—Limitations ... - JAMA Network",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamadermatology/articlepdf/2806310/jamadermatology_obijiofor_2023_le_230001_1692117352.46104.pdf?resultClick=1",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "patients with telogen effluvium ・ only used to treat severe deficiency, and are not recom- mended for long-term use. a randomized clinical",
      "score": 0.33430737
    },
    {
      "number": 3,
      "title": "Telogen Effluvium – a review of the science and current obstacles",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0923181121000086",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### Clin Dermatol. (2013) \n   D.A. Whiting\n### Chronic telogen effluvium: increased scalp hair shedding in middle-aged women\n\n### J Am Acad Dermatol. (1996) \n   S. Malkud\n### A Hospital-based Study to Determine Causes of Diffuse Hair Loss in Women\n\n### J Clin Diagn Res. (2015) \n\n   A.M. Kligman\n### ",
      "score": 0.6894943
    },
    {
      "number": 4,
      "title": "CHRONIC TELOGEN EFFLUVIUM - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0733863505703983",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: CHRONIC TELOGEN EFFLUVIUM - ScienceDirect\n# CHRONIC TELOGEN EFFLUVIUM. Common causes of diffuse alopecia affecting the entire scalp include classic acute telogen effluvium,10 anagen effluvium,16, 18 drugs,3, 4 hypothyroidism,6 iron deficiency,12, 13 and nutritional disturbances.17 In many ins",
      "score": 0.6496014
    },
    {
      "number": 5,
      "title": "Chronic telogen effluvium: Increased scalp hair shedding in middle-aged women - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0190962296901139",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "# Clinical and laboratory study Chronic telogen effluvium: Increased scalp hair shedding in middle-aged women. ***Background:*** Diffuse loss of scalp hair is a common problem in middle-aged women. ***Objective:*** The purpose was to establish distinctive clinical and pathologic criteria for the dia",
      "score": 0.6122407
    },
    {
      "number": 6,
      "title": "Covid Induced Telogen Effluvium (CITE) : Indian Dermatology Online Journal",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/idoj/fulltext/2022/13040/covid_induced_telogen_effluvium__cite___an_insight.1.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Acute TE (ATE) is a non-scarring hair loss, usually occurs 3 months after the event that causes hair loss, and lasts up to 6 months, while chronic TE occurs after 6 months. Acute TE is a self-limited disease characterized by unusual hair shedding (>100 shed hair/day) as a consequence of an abrupt sh",
      "score": 0.5104727
    },
    {
      "number": 7,
      "title": "Alopecia in general medicine - ScienceDirect.com",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1470211824027490",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Telogen effluvium is one of the commonest causes of hair loss that presents as increased hair shedding and diffuse thinning 1– 6 months after a triggering",
      "score": 0.50168514
    },
    {
      "number": 8,
      "title": "Chronic diffuse alopecia in women: a retrospective review of ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/ijd.16921",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "A sudden increase in shedding of telogen hairs 2–3 months after a triggering event like severe febrile illness, major surgery, weight loss,",
      "score": 0.38762134
    },
    {
      "number": 9,
      "title": "Use of 5% Topical Minoxidil Application for Telogen Effluvium: An ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17844",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "With its pharmacological effects on the hair cycle to promote the anagen phase, minoxidil can be a preferable treatment option for TE. Indeed,",
      "score": 0.27098197
    },
    {
      "number": 10,
      "title": "Chronic telogen effluvium in women : Journal of the Egyptian Women's Dermatologic Society",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/jewds/_layouts/15/oaks.journals/downloadpdf.aspx?an=01287624-202118030-00008",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "### Results\n\nThere was no significant difference in serum ferritin, zinc, and 25OH vitamin D levels in two groups. The median of ferritin level was suboptimal in both groups (≤40 μg/l). Interestingly, zinc and 25OH vitamin D levels in healthy participants were lower than patients with CTE, but with ",
      "score": 0.52378637
    },
    {
      "number": 11,
      "title": "Role of ferritin, vitamin D, and thyroid... : Al-Azhar Assiut Medical Journal",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/aamj/_layouts/15/oaks.journals/downloadpdf.aspx?an=01157422-202119030-00015",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "## Introduction\n\nTelogen effluvium (TE) is a common clinical problem defined as noninflammatory nonscarring alopecia that is often related to stress, febrile illness, underlying disease, surgery, pregnancy, medication, endocrinal abnormalities (e.g. thyroid diseases), and nutritional disturbances . ",
      "score": 0.5221784
    },
    {
      "number": 12,
      "title": "An Analytical Study of Serum Ferritin, Vitamin D, and Thyroid ...",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/ijdd/fulltext/2022/09010/an_analytical_study_of_serum_ferritin%2C_vitamin_d%2C.2.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Metabolic causes of diffuse hair loss in women include hypothyroidism and severe iron deficiency anemia; other metabolic disturbances, such as liver disorders and chronic renal failure, are also known to cause sparse scalp hair. Nutritional causes of diffuse telogen hair loss are zinc deficiency and",
      "score": 0.49904844
    },
    {
      "number": 13,
      "title": "Systematic approach to hair loss in women - Trüeb - 2010 - JDDG",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/j.1610-0387.2010.07261.x",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "Chronic telogen effluvium is defined as diffuse telogen hair loss that persists > 6 months. It either represents a primary disorder and is a",
      "score": 0.392221
    },
    {
      "number": 14,
      "title": "Telogen effluvium related to post severe Sars‐Cov‐2 infection ...",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/dth.14547",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "We prescribed a galenic lotion with minoxidil 5%, peptide mimicking hair growth factor lotion, and oral supplementation with sulfur amino acid/",
      "score": 0.29169205
    },
    {
      "number": 15,
      "title": "Telogen Effluvium - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=696c5ba7dc96372a6deae059",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "# Telogen Effluvium. Telogen effluvium is a form of nonscarring alopecia characterized by diffuse, often acute, hair shedding. Telogen effluvium is the excessive shedding of resting or telogen hair after some metabolic stress, hormonal changes, or medication. This activity describesthe epidemiology,",
      "score": 0.71829855
    },
    {
      "number": 16,
      "title": "Telogen Effluvium: A Review of the Literature - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320655",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "## Conclusions\n\nA thorough history, clinical examination, and laboratory investigations can aid in the diagnosis of telogen effluvium. Acute telogen effluvium can usually be resolved by removing the underlying causative factors. However, the treatment of chronic telogen effluvium can be challenging ",
      "score": 0.7043437
    },
    {
      "number": 17,
      "title": "Telogen Effluvium: A Review of the Literature",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7320655",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Scalp Biopsy\n\nIt is recommended in cases where telogen loss lasts greater than six months. Performing multiple biopsies increases the diagnostic accuracy of telogen effluvium. In the case of acute telogen effluvium, there is a normal to supernormal anagen:telogen ratio. Follicular miniaturization an",
      "score": 0.6672566
    },
    {
      "number": 18,
      "title": "The Diagnostic Value of Serum Ferritin for Telogen Effluvium: A Cross-Sectional Comparative Study - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882421",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "## Introduction\n\nTelogen effluvium (TE) is common alopecia in women, characterized by diffuse hair loss. TE used to occur in 2–3 months after the surgery, weight loss, high fever, thyroid disease, and other trigger events.1 Female androgenic alopecia (FAGA) also showed diffuse alopecia.2 Currently, ",
      "score": 0.5735118
    },
    {
      "number": 19,
      "title": "C1 PAGE.indd - AAP Publications",
      "detail": "publications.aap.org",
      "url": "https://publications.aap.org/pediatricsinreview/issue-pdf/828505",
      "authors": "publications.aap.org",
      "host": "publications.aap.org",
      "snippet": "(1)(68) Trichoscopy ... You attribute the hair loss to telogen effluvium based on a hair pull test. ... differential diagnosis, several clinical characteristics",
      "score": 0.5404151
    },
    {
      "number": 20,
      "title": "Comparative evaluation of two Unani formulation combinations in the treatment of telogen effluvium: A randomized, single-blind clinical trial - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2097382926000107",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Comparative evaluation of two Unani formulation combinations in the treatment of telogen effluvium: A randomized, single-blind clinical trial - ScienceDirect\n## Clinical Traditional Medicine and Pharmacology. # Full Length Article Comparative evaluation of two Unani formulation combinations i",
      "score": 0.48952848
    },
    {
      "number": 21,
      "title": "Male Type Alopecia - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/male-type-alopecia",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "| Traction alopecia | Tension applied consistently to hair by hairstyling | Hair loss in scalp margins due to applied pressure | Use relaxed hairstyles, minoxidil, Antibiotics, Corticosteroids, Surgical replacement | Topical lotions and creams  |\n| Telogen effluvium | Diffusive hair loss or shedding",
      "score": 0.48630774
    },
    {
      "number": 22,
      "title": "Low-dose oral minoxidil beyond androgenetic alopecia",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2950198926000589",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Chronic telogen effluvium … 36 women treated with 0.25-2.5 mg LDOM daily showed improvement in hair-shedding scores by 1.7 points at 6 months and 2.58 points",
      "score": 0.43510985
    },
    {
      "number": 23,
      "title": "Systematic review: Impact of stem cells-based therapy, and platelet ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2352320423000652",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Original Article. Systematic review: Impact of stem cells-based therapy, and platelet-rich plasma in hair loss and telogen effluvium related to COVID-19.",
      "score": 0.3069117
    },
    {
      "number": 24,
      "title": "Dengue-associated telogen effluvium: A report of 14 patients",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S1027811716301604",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### Results\n\nThere were 14 patients with dengue-associated TE: one Caucasian man and 13 Taiwanese women. The mean age was 40.1 years. The mean time from dengue infection to the onset of hair shedding was 2.1 months and the hair shedding persisted for 2.9 months on average. Ten out of 13 female patie",
      "score": 0.30164018
    }
  ],
  "publishedAt": "2026-09-15T23:50:19.604078+00:00",
  "updatedAt": "2026-09-15T23:50:19.604078+00:00",
  "readingMinutes": 6,
  "slug": "telogen-effluvium"
}